FDA's Orphan Drug Exclusivity Policy May Face Second Court Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA denies seven years of orphan drug exclusivity for Eagle Pharmaceuticals' Bendeka (bendamustine) despite district court ruling in Depomed case rejecting agency's "clinical superiority" requirement.